A new trading day began on November 20, 2023, with Ocular Therapeutix Inc (NASDAQ: OCUL) stock priced at $2.28, up 3.07% from the previous day of trading. During the day, the shares moved up to $2.4101 and dropped to $2.251 before settling in for the closing price of $2.28. OCUL’s price has ranged from $2.00 to $7.96 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 119.20%. Meanwhile, its annual earnings per share averaged -11.96%. With a float of $75.19 million, this company’s outstanding shares have now reached $77.20 million.
The extent of productivity of a business whose workforce counts for 274 workers is very important to gauge. In terms of profitability, gross margin is +91.18, operating margin of -152.74, and the pretax margin is -137.95.
Ocular Therapeutix Inc (OCUL) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ocular Therapeutix Inc is 5.33%, while institutional ownership is 50.95%. The most recent insider transaction that took place on Aug 30, was worth 24,765. In this transaction President and CEO of this company bought 6,500 shares at a rate of $3.81, taking the stock ownership to the 6,500 shares. Before that another transaction happened on Jul 07, when Company’s Chief Medical Officer sold 832 for $4.93, making the entire transaction worth $4,102. This insider now owns 100,531 shares in total.
Ocular Therapeutix Inc (OCUL) Latest Financial update
In its latest quarterly report, released on 9/29/2023, the company reported earnings of -$0.01 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of -137.95 while generating a return on equity of -115.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.96% per share during the next fiscal year.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Here are Ocular Therapeutix Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.11, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.05 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
The latest stats from [Ocular Therapeutix Inc, OCUL] show that its last 5-days average volume of 0.98 million was inferior to 1.13 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 26.64%. Additionally, its Average True Range was 0.26.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 10.91%, which indicates a significant decrease from 24.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 132.88% in the past 14 days, which was higher than the 77.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.80, while its 200-day Moving Average is $4.63. Now, the first resistance to watch is $2.42. This is followed by the second major resistance level at $2.50. The third major resistance level sits at $2.58. If the price goes on to break the first support level at $2.26, it is likely to go to the next support level at $2.18. The third support level lies at $2.10 if the price breaches the second support level.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
With a market capitalization of 186.64 million, the company has a total of 79,419K Shares Outstanding. Currently, annual sales are 51,490 K while annual income is -71,040 K. The company’s previous quarter sales were 15,080 K while its latest quarter income was -520 K.